Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin b12 and folic acid supplementation for advanced non-small cell lung cancer

Onkologie

Volumn 32, Issue 10, 2009, Pages 580-584

  Bosch Barrera, Joaquim ^a   Gaztañaga, Miren ^a   Ceballos, Jaime ^a   Pérez Gracia, José L ^a   López Picazo, José M ^a   García Foncillas, Jesús ^a   Ferrer, Marta ^a   Sanz, María L ^a   Pretel, Maider ^a   Idoate, Miguel A ^a   Gil Bazo, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Folic acid; Non small cell lung cancer; Pemetrexed; Toxic epidermal necrolysis; Vitamin B complex

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FOLIC ACID; GEMCITABINE; MULTIVITAMIN; OPTOVITE; PACLITAXEL; PEMETREXED; PREDNISONE; ROCHEVIT; SUPRADYN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PLEURA BIOPSY; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRICK TEST; SKIN BIOPSY; SKIN TEST; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL NECROLYSIS, TOXIC; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VITAMIN B 12;

EID: 70350782354     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232315     Document Type: Article

References (21)

1. Chattopadhyay S, Moran RG, Goldman ID: Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-417.
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
3. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS: Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 2005;104:2449-2456.
4. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L: Pemetrexed combined with oxaliplatin or carboplatin as firstline treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-696.
5. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
6. Gamboa PM, Sanz ML, Caballero MR, Antépara I, Urrutia I, Jáuregui I, González G, Diéguez I, De Weck AL: Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003;58:312-317.
7. Sanz ML, Maselli JP, Gamboa PM, Oehling A, Dieguez I, de Weck AL. Flow cytometric basophil activation test: A review. J Investig Allergol Clin Immunol 2002;12:143-154.
8. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA: Platinum-based versus non-platinum- based chemotherapy in advanced non-smallcell lung cancer: A meta-analysis of the published literature. J Clin Oncol 2005;23:2926-2936.
9. Rajeswaran A, Trojan A, Burnand B, Giannelli M: Efficacy and side effects of cisplatin- and carboplatin- based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. Lung Cancer 2008;59:1-11.
10. Stinchcombe TE, Socinski MA: Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008;13(suppl 1):28-36.
11. Adjei AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004; 10:4276s-4280s.
12. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 2000;11:435-440.
13. Lopes G, Vincek V, Raez LE: Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006;51:247-249.
14. Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C, Richard MA, Astoul P: Severe cutaneous toxicity after pemetrexed as second line treatment for a refractory non small cell lung cancer. Rev Mal Respir 2007;24:635-638.
15. Bosch-Barrera J, Montero A, López-Picazo JM, García- Foncillas J, Ferrer M, Yuste JR, Gil-Bazo I: Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung Cancer 2009;64:124-126.
16. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
17. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE: Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241-253.
18. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A: Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002;4:CD001435.
19. Laguna C, Martin B, Torrijos A, Garcia-Melgares ML, Febrer I: Stevens-Johnson syndrome and toxic epidermal necrolysis. Actas Dermosifiliogr 2006;97: 177-185.
20. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.
21. Fogh K: Toxic epidermal necrolysis following intake of vitamins and natural medication. Ugeskr Laeger 1995;157:3631-3633.